- Home
- CLLS vs RWAY Comparison
CLLS vs RWAY Comparison
Compare CLLS & RWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | RWAY |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.2M | 321.2M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLLS | RWAY |
|---|---|---|
| Price | $3.69 | $8.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.50 | ★ $11.08 |
| AVG Volume (30 Days) | 44.3K | ★ 344.3K |
| Earning Date | 03-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | ★ 15.75% |
| EPS Growth | N/A | ★ 44.67 |
| EPS | N/A | ★ 1.48 |
| Revenue | $82,551,000.00 | ★ $141,071,000.00 |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $20.68 | $3.74 |
| P/E Ratio | ★ N/A | $6.00 |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $8.35 |
| 52 Week High | $5.48 | $11.73 |
Technical Indicators
Market Signals| Indicator | CLLS | RWAY |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 39.27 |
| Support Level | $3.44 | $8.66 |
| Resistance Level | $3.98 | $8.95 |
| Average True Range (ATR) | 0.21 | 0.21 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 20.28 | 24.70 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.